Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...
Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that the US Food and Drug Administration (FDA) has approved its Yartemlea ...
Molecular Otolaryngology and Renal Research Laboratories, University of Iowa, Iowa City, IA, United States C3 Glomerulopathy (C3G) is a renal disease mediated primarily by dysregulation of the ...
Performances in N.Y.C. Advertisement Supported by Listen to recordings by Maria Dueñas and Daniil Trifonov, works by Thomas Adès and Tania León, and more. London Philharmonic Orchestra; Thomas Adès, ...
Liquid biopsy using circulating tumor DNA (ctDNA) is emerging as a valuable tool in early-stage NSCLC, with the potential to complement or, in some cases, substitute for tissue-based testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback